INFATRINI GOS/FOS

Glavne informacije

  • Zaščiteno ime:
  • Infatrini GOS/FOS nevtralen okus 125 ml plastenka 1x
  • Farmacevtska oblika:
  • peroralna suspenzija
  • Enote v paketu:
  • plastenka 125 ml
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Alopatska drog

Dokumentov

Lokalizacija

  • Na voljo v:
  • Infatrini GOS/FOS nevtralen okus 125 ml plastenka 1x
    Slovenija
  • Jezik:
  • slovenščina

Terapevtski podatki

  • Terapevtska skupina:
  • Hranila za otroke

Drugi podatki

Stanje

  • Source:
  • JAZMP - Javna agencija RS za zdravila in medicinske pripomočke - Slovenia Medicines Agency
  • Status dovoljenje:
  • Živilo
  • Zadnja posodobitev:
  • 18-01-2018

Podatki za bolnike

Infatrini

Izdelek brez glutena.

Dietno (dietetično) živilo za posebne zdravstvene namene.

Infatrini GOS/FOS je pripravljena in s hranili izpopolnjena prehrana, obogatena z GOS/FOS -

edinstveno mešanico galakto- in frukto-oligosaharidov.

Je prehrana za posebne zdravstvene namene, za dietetsko uravnavanje bolezensko pogojene

neprehranjenosti pri dojenčkih in otrocih od rojstva do 18. meseca starosti oz. do 9 kg telesne teže, ki

ne pridobivajo dovolj na telesni teži, ki imajo dodatne potrebe po hranilih in/ali z redukcijo vnosa

tekočin.

Izdelek je primeren peros ali za sondno hranjenje.

100 ml izdelka vsebuje povprečno:

Energijska vrednost 420 kJ

101 kcal

____________________________________

Maščobe 5,4 g

od tega:

-nasičene maščobe 2,2 g

-enkrat nenasičene maščobe 2,1 g

-večkrat nenasičene maščobe 1,1 g

-Arahidonska kislina(A/A) 17,7 mg

-Dokozaheksaenojska kislina(DHA) 17,6 mg

Ogljikovi hidrati(41 En%) 10,3 g

od teh:

- sladkorji 5,7 g

- od tega laktoza 5,2 g

Prehranske vlaknine (1 En%) 0,6 g

Beljakovine (10 En%) 2,6 g

Sol 0,09 g

Vitamini

Vitamin A 81 µg-RE/ER

Vitamin D3 1,9 µg

Vitamin E 2,1 mg-α-TE/ET

Vitamin K 6,7 µg

Tiamin 0,15 mg

Riboflavin 0,20 mg

Niacin 1,2mgNE/EN 0,52 mg

Pantotenska kislina 0,80 mg

Vitamin B

0,11 mg

Folna kislina(Folat) 16 µg

Vitamin B

0,30 µg

Biotin 4,0 µg

Vitamin C 14 mg

Minerali in elementi v sledovih

Na 1,6 mmol 37 mg

K 2,4 mmol 95 mg

Cl 1,7mmol 62 mg

Ca 2,5 mmol 100 mg

P 1,6 mmol 50 mg

1,6 mmol 153 mg

Mg 0,4 mmol 9 mg

Fe 1,2 mg

Zn 0,80 mg

Cu 0,065 mg

Mn 0,016 mg

Mo <8 µg

Se 2,2 µg

Cr <8 µg

I 18 µg

Karatenoidi 35 µg

Nukleotidi 4,3 mg

L-karnitin 2 mg

Holin 17 mg

Inozitol 25 mg

Taurin 7 mg

Osmolarnost živila 305 mOsmol/l

Razmerje energetskih odstotkov (En%): B:M:OH:VLAKNINE = 10,3 : 47,9 : 40,7* : 1,1

*vsebujejo organske kisline in poliole

Navodila za uporabo:

Izdelek hranimo v hladnem in suhem prostoru (4–25°C), zaščiten pred neposredno sončno

svetlobo.

Pred pričetkom hranjenja si moramo skrbno umiti roke. Pri hranjenju uporabljamo le sterilen

pribor.

Neposredno pred uporabo vsebino dobro pretresemo in pred uporabo preverimo temperaturo

Vsebino izdelka lahko prelijte v sterilizirano stekleničko z dudo, čašo ali set za hranjenje z

vrečko.

Izdelek lahko uporabimo hranjenega na sobni temperaturi ali pa ga segrejemo.

Po odprtju plastenke moramo izdelek hraniti v hladilniku (4°C) in ga porabiti v roku 12 ur.

Vsebino enkrat odprte plastenke, ki jo hranimo na sobni temperaturi zaprto, moramo porabiti v

roku 4 ur od odprtja (enako velja v primeru sondnega hranjenja po setu). Po hranjenju

neposredno

plastenke

neuporabljeno

vsebino

zavržemo.

Vedno

neporabljeno vsebino zavržemo.

Navodila za segrevanje

V primeru segrevanja izdelka uporabite vodno kopel (zaprto plastenko potopite v segreto vodo) in pred

samo uporabo preverite temperaturo. Za segrevanje ne uporabljajte mikrovalovne pečice.

Pomembna opozorila:

Natančno sledite navedenim navodilom in pripravite stekleničko z dudo, kot je predpisano

Ne dodajajte ali redčite izdelka, razen v primeru, ko vam zdravnik svetuje drugače

Nepravilna priprava izdelka lahko škoduje vašemu otroku

Izdelek je primeren samo za enteralno uporabo in ni primeren za intravensko uporabo.

Infatrini GOS/FOS se uporablja izključno pod zdravniškim nadzorom oz. nadzorom dietetika,

potem ko so pretehtane vse možne oblike hranjenja, vključno z dojenjem, in je primeren kot

edini vir prehrane.

Izdelek NI primeren za dojenčke, ki ne prenašajo laktoze in/ali beljakovin v kravjem mleku, ter

za bolnike z galaktozemijo.

Sestavine: demineralizirana voda, posneto mleko v prahu, maltodekstrin, rastlinska olja (repično

olje, sončnično olje, kokosovo olje, ki vsebuje soljo lecitin, srednjeverižni trigliceridi(kokosovo in

palmino olje), koruzno olje, enocelična olja), laktoza (iz kravjega mleka), prehranske vlaknine

(galakto-oligosaharidi (iz mlečnega sladkorja) (0.69%), frukto-oligo saharidi (0.08%)), sirotka (iz

mleka), masleno olje (iz kravjega mleka), trikalcijev di-citrat, kalijev citrat, rafinirano tunino ribje

olje, sredstvo za uravnavanje kislosti( citronska kislina), emulgator (mono- in digliceridi maščobnih

kislin), tri kalcijev fosfat, natrijev klorid, natrijev L-askorbat, inozitol, kalcijev hidroksid, holin klorid,

magnezijev karbonat, kalijev hidroksid, di kalijev hidrogen fosfat, tavrin, železov laktat, natrijev

hidroksid, DL-α-tokoferil acetat, beta karoten, cinkov sulfat, citidin 5’-mono fosfat, nikotinamid, L-

karnitin, adenozin 5’-mono fosfat retinil acetat, uridin 5’-mono fosfat dinatrijeve soli, inozin 5’-mono

fosfat dinatrijeve soli, kalcijev D-pantotenat, holekalciferol, guanozin 5’-mono fosfat dinatrijeve soli,

bakrov

glukonat,

D-biotin,

tiamin

hidroklorid,

kalijev

jodid,

natrijev

selenit,

riboflavin,

piridoksin

hidroklorid, folna kislina (folat), fitomenadion, ciano kobalamin, manganov sulfat.

Neto količina: plastenka 125 m, 24 plastenk v transportnem kartonu.

Pakirano v kontrolirani atmosferi.

Sterilizirano po UHT metodi.

Uporabno najmanj do: Datum je označen na spodnjem delu ovojnine na plastenki

Proizvajalec: N.V. Nutricia – Zoetermeer, Nizozemska

Zastopnik in distributer: KEFO d.o.o. Brnčičeva 29, 1231 Ljubljana – Črnuče, tel. : 01 563 41 43

2-11-2018

FDA and DoD formalize collaboration to advance medical products in support of American military personnel

FDA and DoD formalize collaboration to advance medical products in support of American military personnel

FDA and DoD formalize collaboration to advance medical products in support of American military personnel. New Memorandum of Understanding aligns agency efforts to foster the development and use of safe and effective medical products for members of the U.S. military.

FDA - U.S. Food and Drug Administration

30-10-2018

Training courses on “Steering an Expert Knowledge Elicitation” and “Use of the Expert Knowledge Elicitation Guidance in Risk Assessments for EFSA Management” and “Conduct of the Sheffield protocol for an Expert Knowledge Elicitation”

Training courses on “Steering an Expert Knowledge Elicitation” and “Use of the Expert Knowledge Elicitation Guidance in Risk Assessments for EFSA Management” and “Conduct of the Sheffield protocol for an Expert Knowledge Elicitation”

Published on: Mon, 29 Oct 2018 00:00:00 +0100 This report presents the results from an exploratory study in 2016 on clear communication of scientific assessment results. It had a specific focus on the communication of scientific uncertainties in EFSA scientific opinions. Qualitative methods were applied to the design and communication of an opinion summary and uncertainty statements related to that opinion, and to collect evidence on how different stakeholder groups responded to them. The study tested t...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Minister za zdravje Samo Fakin na vljudnostnem srečanju gostil veleposlanika Italijanske republike

Minister za zdravje Samo Fakin na vljudnostnem srečanju gostil veleposlanika Italijanske republike

Danes je prišlo na pobudo italijanske strani  do krajšega vljudnostnega srečanja med ministrom za...

Ministrstvo za zdravje

14-9-2018

Peer review of the pesticide risk assessment of the active substance azadirachtin (Margosa extract)

Peer review of the pesticide risk assessment of the active substance azadirachtin (Margosa extract)

Published on: Thu, 13 Sep 2018 00:00:00 +0200 The conclusions of the EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State, Germany, for the pesticide active substance azadirachtin are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the additional representative use of azadir...

Europe - EFSA - European Food Safety Authority Publications

17-8-2018

Animal Drug Under Fee Amendments Reauthorized Through September 2023 to Allow for FDA’s Continued Timely Review of Animal Drug Applications

Animal Drug Under Fee Amendments Reauthorized Through September 2023 to Allow for FDA’s Continued Timely Review of Animal Drug Applications

On 8/14/18, the Animal Drug and Animal Generic Drug User Fee Amendments of 2018 was signed into law to reauthorize ADUFA and AGDUFA. These programs help FDA maintain a predictable and timely animal drug review process, foster innovation, and expedite access to new therapies for animals.

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

12-6-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s efforts to foster discovery and development of new tools to fight antimicrobial-resistant infections

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s efforts to foster discovery and development of new tools to fight antimicrobial-resistant infections

The increase in serious antimicrobial drug resistant infections is a critical public health concern and a growing threat to patients. FDA is taking steps to combat antibiotic-resistant bacteria.

FDA - U.S. Food and Drug Administration

16-2-2018

Ministrica za zdravje Milojka Kolar Celarc na delovnem obisku gostila ministra za zdravje Republike Kosovo Urana Ismailija

Ministrica za zdravje Milojka Kolar Celarc na delovnem obisku gostila ministra za zdravje Republike Kosovo Urana Ismailija

Na pobudo Ministrstva za zdravje Republike Kosovo se je 15. in 16. februarja 2017 na delovnem obisku...

Ministrstvo za zdravje

8-1-2018

Ministrica za zdravje na slovesni prireditvi Ona ali On - Dejanje leta 2017, Gospodarstvenik leta 2017 in Podjetnik leta 2017

Ministrica za zdravje na slovesni prireditvi Ona ali On - Dejanje leta 2017, Gospodarstvenik leta 2017 in Podjetnik leta 2017

Ministrica za zdravje Milojka Kolar Celarc se je v soboto udeležila tradicionalne slovesne...

Ministrstvo za zdravje

13-5-2011

Danish Pharmacovigilance Update, April 2011

Danish Pharmacovigilance Update, April 2011

In this issue of Danish Pharmacovigilance Update, read about a new contraindication for Telzir® (fosamprenavir) for HIV treatment, reports of blood clots from the use of Vivaglobin®, and new, improved e-forms for reporting suspected adverse reactions and much more.

Danish Medicines Agency

2-10-2018

Telzir (ViiV Healthcare BV)

Telzir (ViiV Healthcare BV)

Telzir (Active substance: Fosamprenavir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6468 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/534/T/93

Europe -DG Health and Food Safety

25-7-2018

Ivemend (Merck Sharp and Dohme B.V.)

Ivemend (Merck Sharp and Dohme B.V.)

Ivemend (Active substance: fosaprepitant) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4984 of Wed, 25 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/743/T/39

Europe -DG Health and Food Safety

11-7-2018

Fosavance (Merck Sharp and Dohme B.V.)

Fosavance (Merck Sharp and Dohme B.V.)

Fosavance (Active substance: Alendronate Sodium / Colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4518 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/619/T/42

Europe -DG Health and Food Safety

10-7-2018

Sovaldi (Gilead Sciences Ireland UC)

Sovaldi (Gilead Sciences Ireland UC)

Sovaldi (Active substance: sofosbuvir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4482 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2798/T/51

Europe -DG Health and Food Safety

11-6-2018

Harvoni (Gilead Sciences Ireland UC)

Harvoni (Gilead Sciences Ireland UC)

Harvoni (Active substance: ledipasvir/sofosbuvir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3759 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3850/T/67

Europe -DG Health and Food Safety

11-6-2018

Vosevi (Gilead Sciences Ireland UC)

Vosevi (Gilead Sciences Ireland UC)

Vosevi (Active substance: sofosbuvir / velpatasvir / voxilaprevir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3775 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4350/T/15

Europe -DG Health and Food Safety

30-5-2018

Epclusa (Gilead Sciences Ireland UC)

Epclusa (Gilead Sciences Ireland UC)

Epclusa (Active substance: sofosbuvir/velpatasvir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3452 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4210/T/27

Europe -DG Health and Food Safety

3-5-2018

Ivemend (Merck Sharp and Dohme Limited)

Ivemend (Merck Sharp and Dohme Limited)

Ivemend (Active substance: fosaprepitant) - Centralised - 2-Monthly update - Commission Decision (2018)2777 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/743/II/37

Europe -DG Health and Food Safety